PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
Compare
LL-37 vs Selank
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
LL-37
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Selank
57 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Mood
184
Recovery
184
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
94
Fatigue
85
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
3
0.2–0.4 mg
96
0.4–0.6 mg
76
0.6–1 mg
5
1–2 mg
2
5+ mg
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
How repeat users are trending
Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 54 days · Based on 35 repeat reporters
Sources (11)
Published sources linked on the LL-37 and Selank wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
- Wiki study page →Source
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
- Wiki study page →Source
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman D, P J, Cm M, et al. Archives of oral biology. 2026
- Wiki study page →Source
PubMed
Selank and short peptides regulate expression of inflammatory genes
Ershov FI, Uchakin PN, Ershova OV. Bull Exp Biol Med. 2017
- Wiki study page →Source
PubMed
Selank, a tuftsin analogue, demonstrates anxiolytic activity
Seredenin SB, Kozlovskaya MM. Bull Exp Biol Med. 2008
- Wiki study page →Source
PubMed
Selank modulates immune system activity
Ershov FI, Uchakin PN. Bull Exp Biol Med. 2010
- Wiki study page →Source
ClinicalTrials.gov
Selank studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Functional Connectomic Approach to Studying Selank and Semax Effects
Panikratova YR, Lebedeva IS, Sokolov OY, et al. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020
- Wiki study page →Source
PubMed
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of experimental biology and medicine. 2022